ArticleJournal of personalized medicine2025
Dupilumab Effectiveness in Patients with Severe Allergic Asthma Non-Responsive to Omalizumab.
Article in Journal of personalized medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Is Asthma Remission a New Achievable Goal? A Review of the Current Drug-Related Evidence and Predictors.Allergy · 2026Review
- Clinical Remission Trajectories Beyond 12 Months in Severe Asthma Patients Continuing a Single Biologic: A Real-World Single SANI Center Cohort.Medical sciences (Basel, Switzerland) · 2026Article
- Review
- Modifying the course of asthma: mechanisms and strategies for clinical remission.Current opinion in allergy and clinical immunology · 2026Review
- Biomarker-Associated Remission After Switching to Dupilumab in Severe Asthma Following Failure of Prior Biologics.Biomedicines · 2025Article
- Carbon Footprint Impact, of Monoclonal Antibodies for Severe Asthma, Administered in Italy.Biomedicines · 2025Article
- Tezepelumab for early-onset severe allergic asthma with persistent airflow limitation and small airway dysfunction: a treatable traits approach.Drugs in context · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.